Overview NOLAN: Naproxen or Loratadine and Neulasta Status: Completed Trial end date: 2015-03-18 Target enrollment: Participant gender: Summary The primary objective of the study is to estimate the difference in bone pain between breast cancer patients receiving chemotherapy and pegfilgrastim and either no prophylactic intervention, prophylactic naproxen, or prophylactic loratadine. Phase: Phase 2 Details Lead Sponsor: AmgenTreatments: LoratadineNaproxen